SCHEMBL21145702

SCHEMBL21145702

CCOc1cc(Cl)c(Cl)c(C=NNC(=O)c2ccc(OC)cc2)c1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
ALDH1A1 P00352 3/20 0.52
LMNA P02545 3/20 0.52
HTT P42858 2/20 0.52
MAPT P10636 6/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 3/20 0.48
HPGD P15428 2/20 0.48
ATM Q13315 2/20 0.48
PTK6 Q13882 1/20 0.48
MIF P14174 1/20 0.47
KMT2A Q03164 6/20 0.46
MEN1 O00255 4/20 0.46
ASF1A Q9Y294 1/20 0.46
PSMD14 O00487 1/20 0.46
BLM P54132 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
HSP90AA1 P07900 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21145700 1.00 KDM4E (0.52) KDM4ESMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL21145727 0.89 ATM (0.62) KDM4ESMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL21145724 0.89 ATM (0.62) KDM4ESMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL21145698 0.86 IDO1 (0.53) KDM4ESMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL21145696 0.86 IDO1 (0.53) KDM4ESMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL21145651 0.83 LMNA (0.55) KDM4EALDH1A1LMNAHTTMAPT
SCHEMBL21145653 0.83 LMNA (0.55) KDM4EALDH1A1LMNAHTTMAPT
SCHEMBL21145737 0.80 PTK6 (0.48) KDM4ESMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL21145735 0.80 PTK6 (0.48) KDM4ESMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL21145693 0.80 LMNA (0.52) LMNAMAPTNPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11166924-B2 N-methyl-d-aspartate receptor allosteric modulators and methods for their use QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) 2021-11-09 US disclosed
US-20190216753-A1 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190216753-A1 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE GRIN2A, GRIN3A, GRIN1 KDM4E 1424/4885SMN1; SMN2 951/4885ALDH1A1 4093/4885
US-11166924-B2 N-methyl-d-aspartate receptor allosteric modulators and methods for their use GRIN2A, GRIN3A, GRIN1 KDM4E 1424/4885SMN1; SMN2 951/4885ALDH1A1 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.